Poliomyelitis

heart failure with pulmonary hypertension :: Article Creator Sensydia Announces First Patient Enrolled In Pivotal Study Of Non-Invasive Cardiac Performance System (CPS™) Sensydia's Cardiac Performance System (CPS™) is designed for fast, safe, and non-invasive cardiac performance assessment that can be performed almost anywhere, avoiding the need to visit a catheterization lab. Source: Sensydia. -- Study evaluates accuracy of CPS compared to gold-standard right heart catheterization to support FDA submission -- LOS ANGELES, April 28, 2025--(BUSINESS WIRE)--Sensydia, a medical technology company pioneering non-invasive cardiac assessment, today announced that the first patient has been enrolled in its multi-center pivotal study to evaluate the accuracy of the Cardiac Performance System (CPS) for hemodynamic assessment as compared to the gold-standard: invasive right heart catheterization. Sensydia's CPS acquires cardiovascular signa...

lam lung :: Article Creator

acute pulmonary congestion :: Article Creator Can High Blood Pressure Make You Breathless? Shortness of breath, medically known as dyspnoea, is a worrying symptom arising from many underlying health problems. While hypertension is often linked to lung or heart problems, the relationship between high blood pressure and dyspnoea requires careful consideration. We spoke to our expert Dr Lakshmi Navya, Consultant- Cardiology, Manipal Hospital, Vijayawada, who explained this connection and how it unfolds in the body. Does High Blood Pressure Cause Shortness of Breath? Hypertension is not a direct cause of breathlessness. However, it dramatically raises the chances of having conditions that cause dyspnoea. Chronic, poorly controlled hypertension can lead to Left Ventricular Hypertrophy (LVH), which is a thickening of the left ventricle of the heart. "This thickening makes it more difficult for the heart to relax and fill with blood, a condit...

pulmonary hypertension supportive therapy :: Article Creator Ensuring Appropriate Access To Pulmonary Arterial Hypertension Therapy Am J Manag Care. 2019;25:-S0 Pulmonary arterial hypertension (PAH) is a progressive, complex disease. PAH is a type of pulmonary hypertension (PH) and can be further categorized into 7 subdivisions, representing a variety of causal and phenotypic factors. Patients with PH, including PAH, are typically fragile and experience multiple comorbidities; they therefore require individualized treatment plans based on their risk status and etiology. Based on a review of clinical evidence, a wide variety of treatment options exist for PAH, including general measures (eg, physical activity and oral anticoagulants), nonspecific pharmacologic intervention (eg, calcium channel blockers), and targeted pharmacologic intervention. Guidelines point to a flexible approach, frequently including upfront or sequential combination therapy, ...

pleural effusion lung cancer :: Article Creator Global Malignant Pleural Effusion Market Will Surge At 6% CAGR And Reach USD 8.06 Billion By 2033 The global malignant pleural effusion market will likely reach a valuation of USD 8.06 billion by 2033, rising from USD 4.5 billion in 2023. The market is slated to grow at a positive CAGR of 6% from 2023 to 2033. This growth can be attributed to rising incidences of pleural effusion disorder as well as a growing awareness of progressive pleural effusion treatments with different types of techniques. Increasing awareness of health and wellness, and advancements in diagnosis techniques and pathology, especially in developing countries, will drive the therapeutics market. Further, increasing research and development efforts to produce novel therapeutics as well as improve the efficacy of existing ones also drive the market growth. Historically, the market observed a CAGR of 4% from 2018 to 2022 and is proj...

end stage copd pulmonary hypertension :: Article Creator

mild pulmonary hypertension means :: Article Creator Dr. Roach: Hypertension Diagnosis Hasn't Been Discussed With Patient Your browser is not supporteddetroitnews.Com detroitnews.Com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use. Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on detroitnews.Com Dear Doctor: Patient Who Took Redux In The Late 1990 Worries About Possible Heart Issues DEAR DR. ROACH: I took the diet drug Redux in the late 1990s. It was pulled off the market due to correlated heart issues. I saw a cardiologist and learned that I had mild to moderate mitral stenosis with regurgitation. It was watched over a period of years, and they eventually determined that I was stable and had few to no symptoms. So, after a discussion with my cardiologist, we deci...